Emma Walmsley, GlaxoSmithKline CEO (Mandel Ngan/AFP via Getty Images)
July 16, 2021 07:29 AM EDT
R&D

A cou­ple weeks af­ter ac­tivist at­tack, Glax­o­SmithK­line un­veils big plans to cre­ate a UK biotech hub

Nicole DeFeudis

Editor

A cou­ple weeks af­ter ac­tivist in­vestor El­liott be­gan its long-await­ed at­tack on CEO Em­ma Walm­s­ley, Glax­o­SmithK­line has un­veiled a plan to sell over a third …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

A service from the Financial Times